Hello,
The FDA recently released a Medwatch alert on serious breathing problems for patients taking gabapentin or pregabalin and other CNS depressants. Also there's been more articles regarding misuse of gabapentin and baclofen (https://www.tandfonline.com/doi/pdf/10.1080/15563650.2019.1687902?needAc...), especially with the initiatives to reduce opioid use and increase use of other pain medications.

With that in mind, have any institutions made any changes or restrictions to the use of gabapentin and the other medications listed? We were considering maybe adding a new drug-disease interaction alert, but this would likely not change practice significantly and probably be overridden.

Thanks!